Nervgen Pharma Corp Stock Analysis
| NGEN Stock | CAD 3.00 0.13 4.15% |
NervGen Pharma Corp is overvalued with Real Value of 2.35 and Hype Value of 2.96. The main objective of NervGen Pharma stock analysis is to determine its intrinsic value, which is an estimate of what NervGen Pharma Corp is worth, separate from its market price. There are two main types of NervGen Pharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect NervGen Pharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of NervGen Pharma's stock to identify patterns and trends that may indicate its future price movements.
The NervGen Pharma stock is traded in Canada on TSX Venture Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Canada. NervGen Pharma is usually not traded on Canada Day, Civic Holiday, Labour Day, Christmas Day, Boxing Day, New Year 's Day, Family Day, Good Friday, Victoria Day. NervGen Stock trading window is adjusted to America/Toronto timezone.
NervGen |
NervGen Stock Analysis Notes
About 23.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.38. NervGen Pharma Corp had not issued any dividends in recent years. NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange. To find out more about NervGen Pharma Corp contact Michael Kelly at 778 731 1711 or learn more at https://www.nervgen.com.NervGen Pharma Corp Investment Alerts
| NervGen Pharma Corp had very high historical volatility over the last 90 days | |
| NervGen Pharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (22.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NervGen Pharma Corp has accumulated about 8.27 M in cash with (11.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3. | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: NervGen Pharma Launches Equity Program for Flexibility - TipRanks |
NervGen Largest EPS Surprises
Earnings surprises can significantly impact NervGen Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.09 | -0.07 | 0.02 | 22 | ||
2024-08-09 | 2024-06-30 | -0.09 | -0.11 | -0.02 | 22 | ||
2023-05-15 | 2023-03-31 | -0.12 | -0.1 | 0.02 | 16 |
NervGen Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 210.92 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NervGen Pharma's market, we take the total number of its shares issued and multiply it by NervGen Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.NervGen Profitablity
NervGen Pharma's profitability indicators refer to fundamental financial ratios that showcase NervGen Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, NervGen Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, NervGen Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of NervGen Pharma's profitability requires more research than a typical breakdown of NervGen Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.76) | (1.85) | |
| Return On Capital Employed | 9.34 | 9.81 | |
| Return On Assets | (1.69) | (1.78) | |
| Return On Equity | 11.14 | 11.70 |
Management Efficiency
NervGen Pharma Corp has return on total asset (ROA) of (0.5314) % which means that it has lost $0.5314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.3027) %, meaning that it generated substantial loss on money invested by shareholders. NervGen Pharma's management efficiency ratios could be used to measure how well NervGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NervGen Pharma's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 11.70 in 2024, whereas Return On Tangible Assets are likely to drop (1.85) in 2024. Intangibles To Total Assets is likely to climb to 0.07 in 2024, whereas Total Assets are likely to drop slightly above 11.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.03) | (0.03) | |
| Tangible Book Value Per Share | (0.04) | (0.04) | |
| Enterprise Value Over EBITDA | (8.39) | (8.81) | |
| Price Book Value Ratio | (79.68) | (83.66) | |
| Enterprise Value Multiple | (8.39) | (8.81) | |
| Price Fair Value | (79.68) | (83.66) | |
| Enterprise Value | 81.3 M | 47.2 M |
Leadership effectiveness at NervGen Pharma Corp is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 1.351 | Return On Assets (0.53) | Return On Equity (2.30) |
Technical Drivers
As of the 23rd of December, NervGen Pharma secures the Downside Deviation of 5.03, mean deviation of 3.84, and Risk Adjusted Performance of 0.0508. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NervGen Pharma Corp, as well as the relationship between them. Please verify NervGen Pharma Corp maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk to decide if NervGen Pharma Corp is priced some-what accurately, providing market reflects its recent price of 3.0 per share.NervGen Pharma Corp Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. NervGen Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for NervGen Pharma Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
NervGen Pharma Outstanding Bonds
NervGen Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NervGen Pharma Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NervGen bonds can be classified according to their maturity, which is the date when NervGen Pharma Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
NervGen Pharma Predictive Daily Indicators
NervGen Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NervGen Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.11 | |||
| Daily Balance Of Power | (0.39) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 2.94 | |||
| Day Typical Price | 2.96 | |||
| Market Facilitation Index | 0.33 | |||
| Period Momentum Indicator | (0.13) |
NervGen Pharma Forecast Models
NervGen Pharma's time-series forecasting models are one of many NervGen Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NervGen Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About NervGen Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how NervGen Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NervGen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NervGen Pharma. By using and applying NervGen Stock analysis, traders can create a robust methodology for identifying NervGen entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding NervGen Pharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.